ATC CODE L04AA24

ABATACEPT

Αμπατασέπτη

Φαρμακολογικό Προφίλ

Πηγή: DrugBank

Περιγραφή & Ένδειξη

Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). It is produced through recombinant DNA technology in mammalian cells. The drug has activity as a selective costimulation modulator with inhibitory activity on T lymphocytes. Although approved for the treatment of rheumatoid arthritis, Repligen has entered a slightly different formulation of CTLA4-Ig into clinical trials (RG2077).

Κύρια Ένδειξη

For the management of the signs and symptoms of moderate-to-severe active rheumatoid arthritis, inducing major clinical response, slowing the progression of structural damage, and improving physical function in adult patients. It is indicated both as a monotherapy and for use in combination with a continued regimen of DMARDs (not including TNF antagonists). Also used for the management of the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in children.

Χρόνος Ημιζωής

16.7(12-23)daysinhealthysubjects,13.1(8-25)daysinRAsubjects.

16.7 (12-23) days in healthy subjects, 13.1 (8-25) days in RA subjects.

Σύνδεση Πρωτεϊνών

Μ/Δ

Δείτε αναλυτικό φαρμακολογικό προφίλ.

+ Περισσότερες Φαρμακολογικές Πληροφορίες

Μηχανισμός Δράσης

Abatacept is a selective costimulation modulator, like CTLA-4, the drug has shown to inhibit T-cell (T lymphocyte) activation by binding to CD80 and …